URMC / Research / Clinical Trials / Study Details CBRS18089 / S1418 / Alissa Huston Basic Study Information Purpose:This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Location: University of RochesterLead Researcher (Principal Investigator) Lead Researcher: Alissa Huston Study Contact InformationStudy Coordinator: Jessica MackowiakEmail: jessica_ellis@urmc.rochester.edu Additional Study Details URMC / Wilmot Cancer Institute /Research / Clinical Trials / Study Details Trial Not Found The study you are looking for is not active at this time. Return to Search